FDA approves Betaconnect electronic autoinjector for multiple sclerosis- Bayer HealthCare
The FDA has approved Betaconnect, from Bayer HealthCare, an electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). Betaconnect will be available exclusively to Betaseron (interferon beta-1b) patients beginning in early 2016.
The new autoinjector offers customizable injection speed and depth settings that allow patients to inject quietly with precision at the touch of a button. Additionally, the automatic needle insertion and retraction with a visual and audio end-of-dose indication lets patients know when the injection is complete.
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.